Precision BioSciences Inc (DTIL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.47+1.36%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Precision BioSciences aims to extend cash through 2028. Revenue was $10.8 million in 2026-Q1. The company has reported recent earnings beats. Clinical data shows progress in hepatitis B treatment.
Revenue is falling fast, with analysts expecting a 58% drop. The company is losing money and has legal challenges. Cash could run out before 2028 without more funding.
The market expects revenue to shrink by about 58% next year. Our fair value is near $24, reflecting a turnaround but with risks.
Breaks if: Revenue falls below $10 million in 2026
Breaks if: Clinical data fails to show elimination of cccDNA
Cash runway does not extend through 2028
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
DTIL represents a speculative growth investment with a focus on advancing clinical trials. The current thesis state is intact but faces volatility due to high risk and mixed recent performance.
The market appears to price DTIL as relatively cheap compared to its peers, with a slight expectations gap. There is a low fragility tier, indicating that current valuations are justified despite the company's loss-making status.
Management is focused on advancing clinical development and maintaining cash runway through 2028. Recent performance has been neutral, with a low probability of missing expectations, but the high-risk nature of the industry remains a concern.
The thesis hinges on the outcomes of ongoing clinical trials and the ability to maintain fiscal discipline. Additionally, broader sector performance and guidance from major healthcare companies could influence DTIL's trajectory.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Yes, our read has weakened. The latest earnings report missed expectations significantly. This miss suggests that the market is repricing the reasons to own DTIL. The stock has dropped sharply, indicating a potential reevaluation of its value.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management aims to extend the company's cash runway through 2028 by leveraging existing cash, milestone proceeds, and fiscal discipline.
Over the next 1 to 3 years, DTIL's prospects depend on clinical advancements and market conditions. Not investment advice.